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ABSTRACT
Diabetes is an endocrinological disorder characterised by chronic hyperglycaemia due to abnormalities
in insulin secretion, insulin action or a combination of both. According to the International Diabetes
Federation, 463 million people worldwide are living with diabetes; 700 million people will be affected
by 2045. The severity of the disease is dependent on the type and the stage of progression; when not
correctly managed, diabetes can lead to potentially life-threatening micro- and macrovascular
complications.
Prior to the discovery of insulin in 1922, the life expectancy of children with diabetes was short and the
prognosis was very poor. The advocated treatment for diabetes was ruthless starvation, an approach
which resulted in a greatly reduced quality of life for malnourished patients. Modern insulin therapy
has revolutionised the management of diabetes. However, the prevention, treatment, and curation of
diabetes will require more sophisticated approaches that address the underlying pathophysiological
mechanisms of disease.
Presently, a number of strategies are focusing on protecting pancreatic beta-cells and normalising serum
glucose levels through immunomodulation. However, the novelty of immunotherapy raises the risk of
unknown long-term complications, and recent studies have reported that immunomodulators currently
in clinical circulation may represent a trigger for a specific type of drug-induced diabetes.
This review will highlight contemporary advances in the classification, aetiopathogenesis, diagnosis
and treatment of diabetes, with special focus on immunomodulatory strategies for the prevention of
pathology and the potential risk for modern immunomodulators to result in drug-induced diabetes.

A BRIEF INTRODUCTION TO DIABETES
“Diabetes is a remarkable affliction, not very frequent among men, being a melting down of the flesh
and limbs into urine… The course is the common one, namely, the kidneys and the bladder; for the
patients never stop making water, but the flow is incessant, as if from the opening of aqueducts... If the
constitution of the disease be completely established; the melting is rapid, the death speedy… The
disease appears to me to have the name ‘diabetes’ as if from the Greek word 𝛿𝜄𝛼𝛽𝜂′𝜏𝜂𝜍 (which signifies
a siphon), because the fluid does not remain in the body...’”.
- Aretaeus of Cappadocia
Diabetes mellitus, henceforth referred to as diabetes, is one of the oldest diseases known to man. First
referenced in the Ebers papyrus dating from 1550 BC, diabetes is intrinsically linked to human history,
and continues to shape humanity to this day. According to the International Diabetes Federation, 463
million people worldwide are currently living with diabetes; and diabetes is considered to be the fastest
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growing public health emergency of the 21st century, with 700 million people estimated to be affected
by 2045 (International Diabetes Federation, 2019).
The clinicopathology of diabetes is associated with the failure of insulin-secretory function, the failure
of insulin action, or a combination of both (World Health Organisation and International Diabetes
Federation, 2016). If not managed correctly, patients with diabetes can deteriorate acutely, leading to
potentially life-threatening short-term syndromes, and long-term complications. As such, diabetes was
historically associated with a very high rate of morbidity and mortality because, until the discovery of
insulin by Banting and Best in 1922, physicians had no effective clinical strategy to alleviate the disease.
For a brief period, from 1915 until 1922, Allen and Joslin recommended a spartan diet of fasting and
undernutrition for patients with diabetes, which successful prolonged the lifespan of these patients at
the expense of their quality of life (Mazur, 2011). Modern strategies – derived from on-going research
into diabetes – are not as grievous, and have heralded an end to the frustrating pre-insulin era.
However, despite substantial efforts to elucidate the pathomechanisms of diabetes in recent centuries,
knowledge of the disease remains incomplete. Approximately 50% of people living with diabetes are
considered to be undiagnosed, and diabetes remains one of the leading contributors to all-cause
mortality (International Diabetes Federation, 2019). In this introductory review, contemporary advances
in the classification, aetiopathogenesis, diagnosis, and treatment of diabetes will be discussed, with
special focus on emerging immunomodulatory strategies and the associated risk of immunotherapyinduced diabetes.

AETIOPATHOLOGICAL CLASSIFICATION OF DIABETES
Chronic hyperglycaemia and metabolic abnormalities are the characteristic features of diabetes
(DeFronzo et al., 2015; Katsarou et al., 2017), but distinguishing between different types is a clinical
challenge. In 1965, the World Health Organisation published its first classification system for diabetes,
which has been periodically updated. The most recent report on classification (World Health
Organisation, 2019) prioritizes clinical care and appropriate treatments (Table 1), introducing two new
classifications alongside revised definitions for pre-existing types.
While providing a global classification system allows for the treatment and management of diabetes
and the harmonisation of international communications, the heterogeneity of diabetes means that
patients may not present with the defining properties of a single type. Therefore, it is important to note
that there remains flexibility in terms of disease classification.
Type 1 diabetes (T1DM)
T1DM is a chronic autoimmune disorder characterised by the failure of insulin-secretory function on a
background of β-cell autoantibodies and β-cell destruction (Katsarou et al., 2017). In T1DM, central or
peripheral tolerance of self-antigens is inevitably lost; and, as a consequence, autoreactive immunocytes
attack – and sometimes kill – respective self-targets (Cooke et al., 2001). The destruction of pancreatic
tissue is erroneously mediated by infiltrative lymphocytes targeting β-cell antigens as a consequence of
the breakdown of peripheral tolerance, and is predominantly under polygenic control as described by
the Eisenbarth model (Herold et al., 2013). The high incidence of monozygotic discordance for T1DM,
however, illustrates the importance of environmental factors, but the precise environmental factors
contributing to T1DM are largely unknown (Redondo et al., 2008).
Diabetogenes in the major histocompatibility complex region of chromosome 6, contribute significantly
to the breakdown of peripheral tolerance in familial aggregates, particularly the HLA-DR3-DQ2/DR4DQ8 genotype (Rich et al., 2009); a further 60 non-HLA loci may enhance the risk (Regnell and
Lernmark, 2017). Pancreatic β-cell autoantibodies are detectable prior to clinical diagnosis, and were
first described in patients with autoimmune polyendocrine syndrome (Bottazzo et al., 1974; Maccuish
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et al., 1974). The most common and well-defined autoantibodies in T1DM are reactive against insulin,
glutamic acid decarboxylase (GAD65), insulinoma-associated protein 2 (IA-2) and zinc transporter 8
(ZNT8) (Purcell et al., 2019). Several new autoantigens have recently been discovered, including
peripherin, tetraspanin-7, prolyl-4 hydroxylase, and islet amyloid polypeptide; however, neither their
aetiopathological contribution nor diagnostic significance has been investigated (Purcell et al., 2019).
The first autoantibodies detectable in diabetes are usually anti-insulin or anti-GAD65. The appearance
of anti-insulin autoantibodies typically occurs at 1 – 2 years of age, and is rare before 6 months of age
(Ilonen et al., 2013); in contrast, anti-GAD65 autoantibodies do not appear until later in childhood
(Ilonen et al., 2013). IA-2 and ZnT8 rarely appear as the first autoantibodies (Regnell and Lernmark,
2017), but are associated with a more severe pathophysiology (Katsarou et al., 2017).
The identification of a single autoantibody is a poor predictor of T1DM and the probability increases
proportionally to the number of detectable autoantibodies (Regnell and Lernmark, 2017). According to
The Environmental Determinants of Diabetes in the Young (TEDDY) study, the rate of progression to
overt T1DM within 5 years of seroconversion was estimated to be 11%, 36% and 47% in those with
one, two or three autoantibodies, respectively (Törn et al., 2016). However, even with multiple
autoantibodies present, the rate of disease presentation varies with the age of seroconversion and the
autoantibody titre, affinity, and type (Törn et al., 2016).
Recently, two elegant studies using imaging mass cytometry have shown that immune cell infiltration
of the pancreatic islets, known as insulitis, is the histopathological hallmark of T1DM as opposed to the
appearance of autoantibodies (Damond et al., 2019; Wang et al., 2019). The authors hypothesise that
insulitis precipitates a phenotypic change in β-cells prior to their destruction, as an early attempt to
evade the autoimmune response. Although the Eisenbarth model does not account for insulitis, the
model underpins the modern staging of T1DM.
Type 2 diabetes (T2DM)
T2DM is a chronic disorder characterised by reduced insulin production, insulin resistance, and β-cell
dysfunction (DeFronzo et al., 2015). Insulin resistance is defined as an hyperinsulinaemic state
necessary to initiate a glucose-lowering response in patients unresponsive to pre-prandial and postprandial normoinsulinaemia, and hyperinsulinism is considered central to the aetiopathology of T2DM.
Classically, the Felber model describes the two-stage natural history of T2DM (Felber et al., 1987).
Accumulation of ectopic lipid contributes to progressive insulin insensitivity, and pancreatic β-cells
respond by increasing the production of insulin. However, eventually the functional reserve of the
pancreas fails, and overt diabetes develops. This rise and fall in insulin levels is referred to as Starling’s
curve of the pancreas, and typically precedes T2DM by several years (Ha et al., 2016).
Genome-wide association studies have shown that T2DM is a complex polygenic disease. The
heritability of T2D is estimated to range from 20% - 80%, and more than 120 genetic variants have
been implicated (Prasad and Groop, 2015). As such, the development of T2DM cannot be explained
solely by polymorphic variation. Obesity and physical inactivity are the major environmental risk
factors for T2DM, which predispose individuals to β-cell stress and subsequent β-cell failure (Dendup
et al., 2018). Although there is evidence to suggest that additional environmental factors, such as food
environment, physical activity environment, and neighbourhood environment, may contribute to the
risk of T2DM, there is an inadequate availability of evidence in the literature to suggest causality
(Dendup et al., 2018).
Hybrid forms of diabetes
The most recent report by the World Health Organisation on classification proposed two hybrid forms
of diabetes: slowly evolving immune-mediated diabetes and ketosis-prone T2DM (World Health
Organisation, 2019).
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Slowly evolving immune-mediated diabetes, also known as ‘latent autoimmune diabetes in adults’,
‘type 1.5 diabetes’, or ‘double diabetes’, describes cases which are clinically intermediate between
T1DM and T2DM (Khawandanah, 2019). There are no accepted criteria for the diagnosis of this
subtype, however three clinical findings are often indicative of slowly evolving immune-mediated
diabetes: positivity for anti-GAD65 autoantibodies, an age older than 35 years at diagnosis, and no need
for insulin therapy in the first 6 – 12 months after diagnosis (Khawandanah, 2019). The co-presentation
of autoimmune-associated insulin deficiency and obesity-associated insulin resistance has led to
considerable discussion as to whether slowly evolving immune-mediated diabetes is a distinct clinical
entity. Wilkin (2001) proposed the ‘accelerator hypothesis’ as a counterargument, which states that
T1DM and T2DM are not different diseases but rather separate stages of a diabetic continuum that will
eventually culminate in insulin resistance. Wilkin postulates that T1DM (‘fast tempo diabetes’) and
T2DM (‘slow tempo diabetes’) progress towards end-stage β-cell dysfunction at different rates, and that
body mass plays a key role in determining the time-point at which insulin resistance develops (Wilkin
et al., 2016).
Diabetic ketoacidosis and hyperosmolar hyperglycaemic syndrome were historically considered lifethreatening manifestations of T1DM and T2DM, respectively. However, these medical emergencies are
not mutually exclusive, and ketosis-prone diabetes has been increasingly recognised in the absence of
autoimmune T1DM (French et al., 2019). Longitudinal cohort studies suggest that patients typically
present with severe ketoacidosis, suggestive of severe insulinopenia, that progresses to a T2DM-like
disease after resolution with insulin therapy (Mauvais-Jarvis et al., 2004). The underlying
pathophysiology of ketosis-prone T2DM is largely unknown, but an increased propensity to glucose
toxicity is thought to play a role in the transient β-cell failure of ketosis-prone T2DM (Mauvais-Jarvis
et al., 2004).
Hyperglycaemia first detected during pregnancy (HFDP)
In accordance with the results of the Hyperglycaemia and Adverse Pregnancy Outcomes Study and the
recommendations outlined by the International Association of Diabetes and Pregnancy Study Group,
the World Health Organisation recognises two categories of HFDP (World Health Organisation, 2019):
diabetes in pregnancy, defined by the same criteria as overt diabetes in non-pregnant individuals; and
gestational diabetes, defined as spontaneous hyperglycaemia caused by glucose intolerance in
pregnancy based on lower diagnostic cut-off points. Gestational diabetes usually resolves post-partum
and is considered to be an aberrant manifestation of the insulin resistance of pregnancy, which facilitates
the transplacental delivery of glucose to foetal tissues; however, the diagnosis of gestational diabetes
confers an increased lifetime risk of T2DM of approximately 60% (Noctor, 2015).
Other specific types of diabetes
Monogenic diabetes is defined as a specific type of diabetes due to a single autosomal or mitochondrial
gene defect in β-cell function or insulin action, recently reviewed in detail by Misra and Owen (2018).
Monogenic diabetes is broadly sub-classified according to the age of presentation into neonatal diabetes
and maturity onset diabetes of the young, which require distinct treatments from the universal care for
T1DM and T2DM (Misra and Owen, 2018). A diabetic phenotype can also occur secondary to
precipitating disorders or factors, as shown in Table 1.
Unclassified diabetes
Historically, T1DM was classified as a ‘juvenile disease’ because it represented ≥85% of cases of
diabetes among paediatric and adolescent populations (Maahs et al., 2010). However, the prevalence of
T2DM in juvenile cohorts has increased significantly in recent decades, in proportion to an increasing
prevalence of global obesity (Dendup et al., 2018). There is also a growing appreciation that errors are
made when diagnosing T1DM in adulthood because of the higher background prevalence of T2DM,
despite an understanding that T1DM can present across the first six decades of life (Diaz-Valencia et
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al., 2015). It is recommended by the World Health Organisation that ‘unclassified diabetes’ be used to
guide treatment until a definite diagnosis has been made (World Health Organisation, 2019).
Pre-diabetes
Although not included in the 2019 classification system, the World Health Organisation also recognises
pre-diabetes, defined as the presence of impaired fasting glucose (IFG) and/or impaired glucose
tolerance (IGT), as a means of identifying individuals at risk of developing T2DM (World Health
Organisation and International Diabetes Federation, 2016). IFG is defined according to abnormal
fasting plasma glucose concentrations, whereas IGT is defined by an abnormal 2-hour plasma glucose
concentration after a 75 gram glucose load (World Health Organisation and International Diabetes
Federation, 2016). IFG and IGT represent transitionary states between normal glucose homeostasis and
diabetes, and studies have indicated that approximately 70% of patients with pre-diabetes will progress
insidiously to overt diabetes if not managed appropriately (Heianza et al., 2011).

CLINICOPATHOLOGY OF DIABETES
The clinical presentation and severity of symptoms in patients with diabetes is associated with the type
and the duration of disease. The International Diabetes Federation (2019) estimates that T2DM
represents approximately 90% of all individuals diagnosed with diabetes, T1DM, approximately 5%10%, and the remaining types, approximately 1-3%. The symptomatology of diabetes is usually more
severe in patients with T1DM; patients with T2DM may be asymptomatic.
Most diabetic patients present with polyuria, polydipsia, polyphagia, and inappropriate weight loss, as
a consequence of hyperglycaemia and insulinopenia (DeFronzo et al., 2015; Katsarou et al., 2017).
However, The Study to Help Improve Early evaluation and management of risk factors
Leading to Diabetes SHIELD, a 5-year observational study of individuals with or at risk for diabetes
diagnosis, reported that 48% of T1DM patients and 44% of T2DM patients had little symptomatology
(Clark et al., 2007).
Early detection is crucial, as diabetes is associated with a significant morbidity if left untreated: the
microvascular complications of diabetes include retinopathy, nephropathy, and neuropathy; and, the
macrovascular complications are primarily coronary artery disease, peripheral arterial disease, and
cerebrovascular disease (DeFronzo et al., 2015; Katsarou et al., 2017). Diabetes-associated
vasculopathology arises in part due to longstanding hyperglycaemia, which activates a number of
pathogenic pathways including enhanced polyol flux, hexosamine flux, advanced glycation end product
formation, and intracellular oxidative stress (Forbes and Cooper, 2013). Cardiovascular disease remains
a major contributor to all-cause mortality among diabetic patients (International Diabetes Federation,
2019); despite a decline in the global risk of cardiovascular disease, diabetes increases the risk of major
cardiovascular events by two- to four-fold compared with non-diabetic individuals (Harding et al.,
2019).
In severe cases, diabetic ketoacidosis and hyperosmolar hyperglycaemic syndrome are life-threatening
manifestations of T1DM and T2DM, respectively (World Health Organisation and International
Diabetes Federation, 2016). If identified in appropriate time, the mortality of diabetic ketoacidosis has
fallen to less than 1% due to the availability of exogenous insulin therapy (French et al., 2019). In
contrast, hyperosmolar hyperglycaemic syndrome accounts for less than 1% of diabetes-associated
hospital admissions but carries a 10-20% mortality rate (Fadini et al., 2011).
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DIAGNOSIS OF DIABETES
The diagnosis of diabetes is primarily based on the demonstration of hyperglycaemia (World Health
Organisation and International Diabetes Federation, 2016). Persistently elevated blood glucose results
in the formation of glycated haemoglobin (HbA1c), first described by Rahbar et al. (1969), which
correlates with individualistic glycaemic control. Long-term prospective studies, including the Diabetes
Control and Complications Trial, the UK Prospective Diabetes Study Group, and the Epidemiology of
Diabetes Interventions and Complications study, provided definite evidence that HbA1c levels track
the risk of diabetes-associated complications (Nathan et al., 2009). In 2011, the World Health
Organisation recommended the inclusion of HbA1c testing as a diagnostic criterion for diabetes. The
modified diagnostic criteria for diabetes are briefly outlined in Table 2.

THE ERA OF IMMUNOMODULATION IN DIABETES
Diabetes is a chronic, lifelong disease, and avenues for curation are not yet universally available. As
such, the treatment and management of diabetes aims to prevent the acute decompensation of the
individual, delay or arrest the development of diabetes-associated complications, decrease the rates of
morbidity and of morality, and enhance the overall quality of life. Currently, there is no effective and
safe activity for the prevention of T1DM, and the gold standard for improving glycaemic control is
exogenously administered insulin (World Health Organisation, 2019). Since T2DM is predominantly
an environmental problem, prevention by non-pharmacological interventions are very promising;
however, when lifestyle modifications are not sufficient to regularise blood glucose levels,
pharmacological agents have been shown in randomised clinical trials to be effective modalities for the
prevention of T2DM (DeFronzo et al., 2015).
Over the past three decades, a revolution in biomedical research has steered global focus towards
immunological intervention as a preventative modality for individuals with diabetes, in an attempt to
overcome the limitations of exogenous insulin therapy and to lessen disease-related morbidity and
mortality. Current immunomodulatory strategies for diabetes are categorised according to the stage
during which preventative action is initiated: primary immunomodulation aims to prevent
autoimmunogenesis prior to the appearance of β-cell autoantibodies; secondary immunomodulation
aims to prevent pathogenesis following the appearance of β-cell autoantibodies; and tertiary
immunomodulation aims to prevent symptomatic pathoprogression following the diagnosis of disease
(Figure 1). For this review, tertiary immunomodulation is further categorised as antigen-independent,
antigen-dependent, or β-cell specific. Most studies have focused on tertiary immunomodulation in
recent-onset T1DM as subjects are easy to identify; few studies have evaluated immunomodulation in
T2DM.
Primary immunomodulation
The great majority of primary immunomodulation trials have focused on dietary manipulation or
supplementation. Epidemiological investigations and meta-analyses suggested that early exposure to
dietary components in bovine milk potentiated the development of β-cell autoantibodies, which lead to
a Finnish pilot study in 1995, evaluating whether the risk of autoimmunity was abrogated by weaning
to hypoallergenic hydrolysed formulae (Knip et al., 2010). Initial reports indicated that the risk of
development of β-cell autoantibodies was reduced in high-risk infants (Knip et al., 2010), however
extensive follow-up of 2,159 infants in the subsequent TRIGR study found no benefit of weaning to
hydrolysed formulae (Knip et al., 2018). In addition, recent studies have shown that there is no benefit
to delayed introduction of gluten-containing foods (Beyerlein et al., 2014), polyunsaturated fatty acid
supplementation (Brown et al., 2019), nor vitamin D3 supplementation (Pittas et al., 2019). However,
the Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabetes (FINDIA) study reported
that weaning to a formula free of bovine insulin benefitted infants genetically susceptible to T1DM

The International Undergraduate Journal of Health Sciences
https://sword.cit.ie/iujhs/vol1/iss1/3

25
6

Harte: Diabetes Mellitus and Immunomodulation.

IUJHS

June 2021

Volume 1 Issue 1

(Vaarala et al., 2012), and a recent study in animal models observed benefits from increased short-chain
fatty acid consumption (Mariño et al., 2017).
Secondary immunomodulation
Following the appearance of β-cell autoantibodies, studies of secondary immunomodulation have
largely failed to prevent the pathoprogression of diabetes. Clinical trials investigating the tolerogenic
effect of intradermal, oral, and nasal insulin have repeatedly been unsuccessful. The administration of
exogenous nicotinamide and nicotinamide-derivatives has been shown to be protective against diabetes
in non-obese diabetic mice models (Trammell et al., 2016), but similar endpoints have not been
observed in human studies (Lampeter et al., 1998; Fukaya et al., 2013).
One possible explanation for the failure of prior secondary immunomodulatory trials may be the time
of intervention. A post-hoc analysis of participants in the Diabetes Prevention Trial–Type 1 study
showed that oral insulin delayed the onset of T1DM only when high levels of anti-insulin antibodies
were detectable (Vehik et al., 2011). Therefore, secondary immunomodulatory studies may need to
consider the time of intervention, the age at the time of diagnosis, the baseline insulin-secretory
function, and the extent and type of seroconversion. In light of these findings, a phase III clinical trial
is currently underway (Ziegler et al., 2019) that aims to prevent T1DM through daily high-dose oral
insulin based on the preliminary success of the Pre-POINT study (Bonifacio et al., 2015).
Tertiary antigen-independent immunomodulation
Monoclonal antibody therapy
Several monoclonal antibodies targeting T-lymphocytes have been trialled in patients newly diagnosed
with diabetes, with varying successes. For example, rituximab (anti-CD20) preserved insulin-secretory
function in patients with diabetes as shown by lower HbA1c levels and reduced insulin requirements
(Pescovitz et al., 2009); however, extended follow-up of participants treated with rituximab showed
that improvement was transient and that the monoclonal antibody did not significantly alter the
pathophysiology of the disease (Pescovitz et al., 2014). In contrast, teplizumab (anti-CD3) was shown
to prevent the progression to clinical T1DM in high-risk participants (Herold et al., 2019); although,
patients with the HLA-DR3 allele or anti-ZnT8 antibodies did not respond as favourably to teplizumab
(Herold et al., 2019), highlighting the heterogeneity of diabetes.
Cytokine inhibition therapy
Proinflammatory cytokines play a pivotal role in the development of diabetes, and the inhibition of
cytokine expression has been noted to induce important cytoprotective changes in pancreata (Lopes et
al., 2014). Interleukins (IL) are powerful immunomodulators that significantly influence the
pathogenesis of diabetes, exerting inhibitory, cytostatic, pro-necrotic and pro-apoptotic effects (Gouda
et al., 2018). Studies of IL-1 pharmacological antagonism and monoclonal blockade have suggested
that IL-1 inhibition could preserve pancreatic tissue if combined with additional treatments (Moran et
al., 2013).
Furthermore, ciliary neurotrophic factor (CNTF) is known to improve insulin resistance by competing
with pro-diabetogenic IL-6 for the gp130 receptor (Watt et al., 2006). A recombinant human CNTF
protein initially demonstrated promise for the treatment of obesity and T2DM (Ettinger et al., 2003),
however development was halted after some patients produced antibodies which had the potential to
interfere with endogenous signalling (Ettinger et al., 2003). Findeisen et al. (2019) constructed a
chimeric IL-6-CNTF cytokine, referred to as ICF7, to overcome the limitations of recombinant
technology. ICF7 has been shown to decrease adiposity, preserve lean mass, enhance insulin-secretory
function, and increase bone stability in animal models, without triggering the deleterious proinflammatory effects of IL-6 that are known to contribute to insulin resistance (Findeisen et al., 2019).
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Bioengineered cytokines, such as ICF7, may represent realistic next-generation biological agents for
the preventative treatment of T2DM.
Regulatory T-cell therapy
Regulatory T-cells are a specific subpopulation of T-cells that are engaged in sustaining immunological
self-tolerance and homeostasis, functioning to suppress the potential deleterious effects of the immune
response. Regulatory T-cell deficiency or dysfunction is considered to be a precipitating factor for the
development of β-cell autoantibodies (Sharabi et al., 2018). A two-hit hypothesis has been postulated
from studies of regulatory T-cell deficiency or dysfunction in animal models to explain the switch from
insulitis to overt diabetes (Cabrera et al., 2012): initially, pancreatic regulatory T-cells suppress
autoreactive, insulitic counterparts; eventually however, regulatory T-cells fail to suppress effector cells
and overt autoimmunity develops.
Preliminary studies have examined the role of ex vivo expanded autologous regulatory T-cells on the
pathoprogression of T1DM (Bluestone and Tang, 2004; Weber et al., 2006; Tarbell et al., 2007).
Although the preliminary trials failed to alter the natural history of diabetes, the authors deemed that
sufficient evidence on safety and tolerability was available to warrant further trials to test whether the
expansion of regulatory T-cell populations may indeed prevent diabetes (Bluestone et al., 2015). An
alternative route of regulatory T-cell therapy involves the in vivo induction of peripheral regulatory Tcells by administration of a tolerogenic vaccine consisting of antigenic peptides and an
immunosuppressive agent (Gen et al., 2015). Recently, Zhou et al. (2019) described a tolerogenic
vaccine that prevented the onset of T1DM in non-obese diabetic mice, which is to be considered as a
clinical strategy for the treatment of diabetes.
Furthermore, chimeric antigen receptors (CARs) have emerged as a novel form of immunotherapy.
CARs are bioengineered molecules which redirect autologous T-cell populations to recognise predetermined antigens (Sadelain et al., 2013). The antigen-specific portion of the CAR has an affinity
several orders of magnitude greater than the corresponding T-cell receptor and the activation and
expansion of CAR-T-cells in vivo is independent of the major histocompatibility complex (Feins et al.,
2019). A recent study by Tensplode et al. (2019) demonstrated that insulin-specific CAR-regulatory-Tcell populations were stable, durable, and suppressive in diabetic mice, and could potentially protect
pancreatic mass and insulin-secretory function; although, as documented previously, studies from
animal models do not always successfully extrapolate to humans.
Tertiary antigen-dependent immunomodulation
In contrast to antigen-independent immunomodulation, antigen-dependent strategies attempt to elicit
specific tolerisation of autoreactive immune cells without suppression of the immune response. In this
context the immune system is trained to tolerate antigenic peptides against which a dramatic response
would normally occur (Cooke et al., 2001), and the successes and failings of this stratagem have been
extensively reviewed by Smith and Peakman (2018).
Briefly, peptide immunotherapy restores immunological balance by suppressing autoreactive T-cells
that recognise pancreatic antigens and by promoting the expansion of regulatory T-cell populations
which Smith and Peakman conclude may translate into a safe, effective, and highly specific class of
designer therapeutics (2018). As examples, the administration of proinsulin was shown to modulate
autoreactive CD4+ T-cells and to preserve insulin-secretory function as measured by higher C-peptide
levels in diabetic patients (Thrower et al., 2009), and Bayesian meta-analysis suggests that
administration of GAD65 could yield a positive effect on insulin production (Beam et al., 2017).
Tertiary β-cell-specific therapy
β-cell-specific therapies focus on restoring the in vivo functionality of pancreatic islets. The Edmonton
protocol involves transplanting an adequate mass of pancreatic islets from deceased donors to
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immunosuppressed recipients, and is currently the sole therapy capable of bringing about glycaemic
control without exogenous insulin (Faradji et al., 2008). The advantage of the Edmonton protocol is
that transplanted islets can regulate glucose homeostasis and circulating insulin levels more efficiently
than exogenously administered doses. However, the adverse events associated with the
immunosuppressive regimen required for the successful transplantation of pancreatic tissue is the
primary concern limiting the universal implementation of the Edmonton protocol (Shapiro et al., 2006).
The cost of pancreatic islet procurement is also a significant challenge (Bottino et al., 2018).
The number of islets required for the Edmonton protocol could be reduced using β-cell-specific
regenerative strategies, such as stem cell therapy or the administration of pharmacological agents which
stimulate gastrin and glucagon-like peptide-1. Gastrin and glucagon-like peptide-1 induce regeneration
and differentiation of pancreatic β-cells, and have shown promise in the non-obese diabetic mice
(Suarez-Pinzon et al., 2009). In humans, the Combination Therapy With Sitagliptin and Lansoprazole
to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes (REPAIR-T1D) study failed
to show any positive effect (Griffin et al., 2014); however, the authors claims that further trials are
necessitated to establish the appropriate dosages, as the increase in gastrin and glucagon-like peptide-1
was deemed ineffectively low.

THE FUTURE OF IMMUNOMODULATION – MICROBIOME THERAPY
First proposed by Lederberg and McCray in 2001, the microbiome is a rich, ecological community of
mutualistic microorganisms that inhabit humans. The physiological and metabolic influences of the
intricate interrelations between the microbiome and the host are well established, and there is a growing
appreciation that the composition of the microbiome can have pathological or pathoprotective
properties. A dysfunctional microbiome is considered to be a risk factor for the development of diabetes.
In 2008, Vaarala et al. postulated an elegant model to explain the pathogenic relationship between the
microbiome and the development of diabetes. Vaarala’s mechanistic triad included increased
gastrointestinal permeability, immunological dysregulation, and abnormal alterations in the
microbiome – termed ‘dysbiosis.’ Studies have since demonstrated that a reduced bacterial diversity,
characterised by lower levels of Firmicutes and Clostridia and an increased Bacteroidetes-Firmicutes
ratio is associated with T1DM (Brown et al., 2011), T2DM (Graessler et al., 2013), and pre-diabetic
states (Allin et al., 2018); therefore, re-establishing a healthy microbiome may represent a promising
modality for the prevention of diabetes.
Mycobacterium are among the oldest members of the human microbiota, forming an evolutionary
partnership that spans over 90,000 years. Reintroduction of Mycobacteria can epigenetically train the
host immune system, resulting in unexpected and heterologous effects. A ‘proof of concept’ trial of the
bacillus Calmette-Guerin (BCG) vaccine in patients with long-term T1DM demonstrated promising
results, including a transient increase in insulin-secretory function, although a reduced HbA1c level was
not observed (Faustman et al., 2012). The recently published results of an eight-year long Phase 1 trial
aiming to investigate the clinical effects of two doses of BCG Connaught strain vaccine, four weeks
apart, in 282 human participants, show that BCG-vaccinated patients developed long-term, stable and
near normal blood glucose levels (Kühtreiber et al., 2018). The authors propose that reintroduction of
avirulent Mycobacteria causes a global switch in the metabolism of immune cells from oxidative
phosphorylation to augmented Warburg glycolysis, similar to the immunometabolic alterations seen
with infectious Mycobacterium tuberculosis (Shi et al., 2015). This systemic change results in the
consumption of excess blood glucose in a gradual manner to safely restore normoglycaemia and normal
HbA1c levels. Unlike other strategies, it is anticipated that this novel form of immunomodulation may
also be applicable to T2DM.
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IMMUNOTHERAPY-INDUCED DIABETES
Although immunomodulation in diabetes is an evolving field, immunotherapy is an established
cornerstone of disease treatment. In recent decades, exploitation of the immune system to treat cancer
has become progressively more favourable. Human cancers originate from genetic instability and
mutations, which can result in the expression of neo-epitopes. The immune system recognises and
eliminates pre-cancerous and/or cancerous cells through immunosurveillance of non-self, cancerspecific antigens. One of the hallmarks of cancer is counteractive immunomodulation, whereby
abnormal cells activate different immune checkpoint pathways that suppress cytotoxic responses and
allow pre-cancerous and/or cancerous cells to escape immunological clearance (Fouad and Aanei,
2017).
Programmed death-ligand 1 (PD-L1) is an immune checkpoint that negatively regulates immune
responses through interaction with the programmed cell death protein 1 (PD-1) receptor expressed on
immune cells. The role of the PD-L1/PD-1 axis is to regulate T-cell activity in order to prevent
inappropriate immune responses and promote self-tolerance (Akinleye and Rasool, 2019). Deficiency
or excess in the PD-L1/PD-1 axis can lead to a variety of immune-associated pathologies (Qin et al.,
2019). In order to escape immunosurveillance, cancer cells enhance their expression of PD-L1; it is
estimated that 5-40% of cancer cells overexpress PD-L1 (Xiang et al., 2018). Cancer immunotherapy
utilises monoclonal antibodies that inhibit the PD-L1/PD-1 axis to reinvigorate immunological
clearance by interrupting co-inhibitory signalling pathways in immune cells, significantly enhancing
clinical response rates and prolonging survival.
However, immune checkpoint inhibitors have also been linked to a number of adverse events.
Hyperglycaemia is seldom included as a possible side-effect of immune checkpoint inhibitors but
reports of immunotherapy-induced diabetes (IDD) can be increasingly found in the literature. In
preclinical studies, inhibitors of PD-1 were shown to accelerate the onset of T1DM (Ansari et al., 2003)
and restoration of the PD-L1/PD-1 axis reversed the diabetic phenotype (Wang et al., 2005). In humans,
case studies in the literature provide evidence of a link between new-onset diabetes and several immune
checkpoint inhibitors, including nivolumab (anti-PD-1; Godwin et al., 2017), pembrolizumab (anti-PD1; Presotto et al., 2019), cemiplimab (anti-PD-1; Markham and Duggan, 2018), atezolizumab (anti-PDL1; Sothornwit et al., 2019), avelumab (anti-PD-L1; Shibayama et al., 2019), and durvalumab (antiPD-L1; Chia et al., 2019). The precise pathophysiology of IDD is not clear but is suspected that immune
checkpoints have a prominent role in the regulation of β-cell tolerance (Dehghani et al., 2018). An
overview of the pathophysiology of IDD is presented in Figure 2.
The incidence of IDD is estimated to approach 1% of patients treated with PD-L1/PD-1 inhibitors
(Stamatouli et al., 2018), and a recent analysis detected 283 cases of recent-onset diabetes associated
with immune checkpoint inhibitors between 2014 and 2018 (Wright et al., 2018). Acute autoimmune
insulin-dependent diabetes is the commonest form of IDD, which manifests similarly to fulminant
diabetes and may be caused by the sudden activation of β-cell-reactive CD8+ cells in response to
immune checkpoint inhibition (Stamatouli et al., 2018). Several cases of IDD have also arisen in
patients with pre-diabetes or T2DM (Stamatouli et al., 2018), suggesting that checkpoint inhibitors can
decompensate glycaemic control by an unknown mechanism. One case was reported following
autoimmune pancreatitis due to immune checkpoint inhibition (Dehghani et al., 2018); two exceptional
cases of IDD were linked to anti-PD-1-induced autoimmune lipodystrophy, characterised by immunemediated destruction of subcutaneous adipose tissue and severe insulin resistance (Falcao et al., 2019;
Jehl et al., 2019).
It is recommended that blood glucose and HbA1c levels be assessed prior to the administration of any
checkpoint inhibitor to exclude pre-existing states of hyperglycaemia, and that blood glucose levels be
regularly monitored, even if this does not systematically diagnose or predict the onset of diabetes (Smati
et al., 2018). Due to the rapid onset of insulinopenia in IDD, the distribution of information is
paramount; patients must be educated to recognize the inaugural symptoms of diabetes and diabetic
ketoacidosis in order to access treatment in a timely manner. Immunotherapy-induced diabetes is
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typically insulin-dependent, and the majority of cases in the literature were treated with doses of
exogenous insulin similar to patients with uncontrolled T1DM (Stamatouli et al., 2018). Interestingly,
a recent case study reported that IDD associated with anti-CTLA-4 and anti-PD-1 was successfully
treated with infliximab, a pharmacological inhibitor of TNF-α (Trinh et al., 2019). The case argues the
use of infliximab to restore insulin-secretory function in patients with IDD, although validation studies
in larger populations are required (Trinh et al., 2019).

CONCLUDING REMARKS
The classification, aetiopathogenesis, diagnosis and treatment of diabetes remains in significant flux
since the writings of Aretaeus of Cappadocia. The discovery of insulin by Banting and Best provided
patients with diabetes a quality of life that was not possible prior to 1922. However, no cure has yet
been identified despite extensive research spanning centuries of scientific endeavour. In essence, global
knowledge of diabetes remains as incomplete as ever. Without a complete understanding of the
pathomechanisms of diabetes, it is unlikely that a durable cure will be found.
However, recent advances in immunomodulatory therapies outlined herein have allowed for an exciting
phase of progression. Modulating the immune system at a primary, secondary, or tertiary stage may
provide an effective strategy for treating and preventing diabetes. The findings from preclinical and
clinical studies support the advancement of immunomodulatory experimentation, and if nurtured
sufficiently immunomodulation could facilitate personalised treatment modalities in the coming
decades. However, a number of strategies will be required, in order to alleviate the many different
classifications of diabetes. The majority of studies have focused primarily on T1DM, which is a
considerable failing to date as T2DM is the most common classification globally, and new types of
diabetes are being continually recognised. Therefore, novel biomarkers will also be required to monitor
the responsivity of patients with diabetes undergoing immunomodulatory therapy, to enable healthcare
professionals to differentiate between ‘responders’ and ‘non-responders’ in line with the prioritisation
of clinical care and appropriate treatment (World Health Organisation, 2019).
Like diabetes itself, the immune system is a complex entity; extensive research is required to fully
delineate the interplay between the host immune system and diabetes. p
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